About Novartis
Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. Formed by the merger of Ciba-Geigy and Sandoz in 1996, Novartis is one of the largest pharmaceutical companies in the world by revenue.
Our Mission
Novartis is reimagining medicine to improve and extend people's lives. The company focuses on innovative medicines in cardiovascular, oncology, immunology, neuroscience, and ophthalmology, serving patients in more than 140 countries.
Key Medicines
Novartis has a strong portfolio including Entresto for heart failure, Cosentyx for immunology, Kisqali for breast cancer, and Zolgensma for spinal muscular atrophy. The company also owns Sandoz, a global leader in generics and biosimilars.
Research & Innovation
Novartis invests approximately $9 billion annually in R&D, with a focus on targeted therapies, gene therapies, and radioligand therapy platforms. The Novartis Institutes for BioMedical Research (NIBR) drives early-stage discovery.
Global Presence
Headquartered in Basel, Novartis employs over 76,000 people worldwide and operates in 140+ countries. The company generated $45.4 billion in revenue in 2023, with strong growth driven by its innovative medicines portfolio.
Leadership
Vasant (Vas) Narasimhan has served as CEO since 2018, leading Novartis through a major transformation toward becoming a focused innovative medicines company.